TEVA, US8816242098

Teva Pharmaceutical Industries stock settles US states' case

Published on 11/17/2026 at 16:59 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Teva Pharmaceutical Industries stock is tied to a settlement with most US states over alleged price fixing involving generic drugs. The case had lasted years.

Settlement changes Teva's legal picture

  • Teva settled litigation brought by most US states over alleged price fixing involving dozens of generic drugs.
  • The case had remained active for years and involved Teva alongside numerous other defendants.
TEVA, US8816242098, Illustration mit AI erstellt.

Teva Pharmaceutical Industries has settled long-running litigation brought by most US states over allegations that the drugmaker and dozens of other defendants conspired to fix prices for numerous generic medicines, Reuters reported on November 16.

Legal exposure moves toward resolution

The settlement addresses claims brought by most US states in a case that had remained active for years. Reuters said the allegations concerned price fixing across dozens of generic drugs and included numerous defendants.

For Teva, the agreement marks a significant legal development in its generics business. The report did not provide settlement terms or an amount, so the immediate financial impact cannot be quantified from the announcement.

Teva Pharmaceutical Industries

  • Company: Teva Pharmaceutical Industries Ltd.
  • ISIN: US8816242098
  • Ticker: TEVA

Broader Israeli market coverage is available through TA-35 market reports.

More news and analyses on Teva Pharmaceutical Industries stock

Disclaimer...
en | US8816242098 | TEVA | boerse | 70527757 | bgmi